[ad_1]
MANILA, Philippines – The Philippines has received at least 30 million doses of the Indian-made Novavax coronavirus vaccine, which could be available by July 2021, Foreign Secretary Teodoro Locsin Jr. said Monday.
In an interview with CNN Philippines, Locsin said the agreement could be signed before the end of the year. He added that the information came from the Serum Institute of India, the world’s largest vaccine producer.
“Thirty million doses of the Indian-made Novavax vaccines are insured possibly without a cash advance. It will be available in July 2021, ”Locsin said.
“The term sheet could be signed before the end of the year,” he added.
American vaccine developer Novavax Inc. had signed an agreement with the Serum Institute of India for the development and commercialization of its COVID-19 vaccine.
READ: Indian Vaccine Maker Promises PH Access to COVID-19 Vaccine Once Available
So far, the Philippines has already obtained more than two million doses of coronavirus vaccines from British pharmaceutical company AstraZeneca through a tripartite agreement it signed with the private sector.
The government is also investigating vaccines from Sinovac Biotech of China, Gamaleya Research Institute of Russia and Moderna, and Pfizer of the United States.
In the same interview, Locsin announced that the vaccine czar, Carlito Gálvez Jr., will begin negotiations with Moderna on or before December 30.
JE
For more news on the new coronavirus, click here.
What you need to know about the coronavirus.
For more information on COVID-19, call the DOH hotline: (02) 86517800 local 1149/1150.
The Inquirer Foundation supports our healthcare leaders and still accepts cash donations to be deposited into the Banco de Oro (BDO) checking account # 007960018860 or donate through PayMaya using link .
Read next
Subscribe to INQUIRER PLUS to get access to The Philippine Daily Inquirer and more than 70 other titles, share up to 5 gadgets, listen to the news, download from 4am and share articles on social media. Call 896 6000.
For comments, complaints or inquiries, please contact us.
[ad_2]